Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Hepatitis

Free Subscription Articles published in J Infect Dis Retrieve available abstracts of 72 articles: HTML format

Single Articles

October 2025
1. SKOVGAARD ET, Wiggers T, Karsdal M, Goetze JP, et al
   Serum markers of fibroinflammatory activity PRO-C3 and CPa9-HNE are associated with liver-related outcomes in patients with Chronic Hepatitis C.
   J Infect Dis. 2025 Oct 31:jiaf552. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. LI X, Shi M, Wang X, Guo F, et al
   Non-invasive detection of occult yet significant liver pathology in ALT-normal chronic hepatitis B: a multicenter study.
   J Infect Dis. 2025 Oct 30:jiaf554. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. CHEN J, Huang Z, Yang X, Yang Y, et al
   Predictors of Durable Hepatitis B Surface Antigen Loss After Pegylated Interferon-Based Therapy in Patients with Hepatitis B e Antigen-Negative Chronic Hepatitis B: A Multicenter Real-World Study.
   J Infect Dis. 2025;232:953-960.
   PubMed     Abstract available
   
   
   
4. DAWES BE, De La Mota-Peynado A, Rezende IM, Buyukcangaz EK, et al
   Rift Valley Fever Virus Infectivity in Milk Stored at a Wide Range of Temperatures.
   J Infect Dis. 2025;232:e661-e670.
   PubMed     Abstract available
   
   
   August 2025
5. KOYUNCU A, Nesbitt R, Alvarez C, Asilaza KV, et al
   Diagnostic performance and kinetics of hepatitis E viral RNA and IgM antibody test positivity in a genotype 1 outbreak in South Sudan.
   J Infect Dis. 2025 Aug 14:jiaf436. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. YU H, Li B, Guo H, Li L, et al
   SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon alpha-Based Therapy on Chronic Hepatitis B.
   J Infect Dis. 2025;232:474-484.
   PubMed     Abstract available
   
   
   
7. MADUT DB, Rubach MP, Allan KJ, Thomas KM, et al
   Epidemiologic and Genomic Characterization of an Outbreak of Rift Valley Fever Among Humans and Dairy Cattle in Northern Tanzania.
   J Infect Dis. 2025;232:298-307.
   PubMed     Abstract available
   
   
   
8. GAO Q, Lan X, Yang F, Yu H, et al
   Prognostic Divergence in HIV/HBV vs. HBV- Associated HCC after Resection: Intrahepatic Pre-S Deletions Mutants and T-cell Depletion under Viral Suppression.
   J Infect Dis. 2025 Aug 14:jiaf433. doi: 10.1093.
   PubMed     Abstract available
   
   
   July 2025
9. VO-QUANG E, Rodriguez C, Ly A, Ndow G, et al
   Virological tools fail to properly identify "unusual" hepatitis C virus subtypes resistant to direct-acting antiviral drugs in The Gambia.
   J Infect Dis. 2025 Jul 22:jiaf378. doi: 10.1093.
   PubMed     Abstract available
   
   
   June 2025
10. BARAGATTI M, Abdoullah B, Gomez N, Ayhan N, et al
    Seroepidemiological Reconstruction of Long-term Rift Valley Fever Virus Circulation in Nouakchott, Mauritania.
    J Infect Dis. 2025;231:e853-e861.
    PubMed     Abstract available
    
    
    May 2025
11. WEGERMANN K, Lucas JE, Dubois L, Mangus R, et al
    Plasma lipid metabolites differentiate metabolic from viral chronic liver disease.
    J Infect Dis. 2025 May 23:jiaf270. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. GRANTZ KH, Anantharam R, Kandathil AJ, Quinn J, et al
    Multiple approaches to genetic sequencing to identify hepatitis C virus reinfection among people who inject drugs.
    J Infect Dis. 2025 May 15:jiaf235. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
13. NDOW G, Bangura R, Vo-Quang E, Touray F, et al
    Residual risk of hepatitis B virus (HBV) mother-to-child transmission and gaps in HBV care cascades among pregnant women in The Gambia: the INFANT-B study.
    J Infect Dis. 2025 Apr 30:jiaf214. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. BEGRE L, Akotia MK, Wembulua BS, Pandi M, et al
    Circulating HBV RNA and conventional HBV markers in treatment-naive persons with HBV in Senegal.
    J Infect Dis. 2025 Apr 19:jiaf190. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2025
15. PAUL RC, Gidding HF, Nazneen A, Banik KC, et al
    Population-based estimates of hepatitis E virus associated mortality in Bangladesh.
    J Infect Dis. 2025 Mar 13:jiaf134. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. DOYLE TJ, Buck BH, Locksmith TJ, McGruder-Rawson BM, et al
    Genomic epidemiology of resurgent hepatitis A in Florida, 2018-2022.
    J Infect Dis. 2025 Mar 11:jiaf127. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
17. GONZALEZ-SERNA A, Corma-Gomez A, Cano M, Ricardo RS, et al
    Influence of Cellular Aging on Liver Stiffness in HCV Patients Achieving Sustained Viral Response.
    J Infect Dis. 2025 Feb 19:jiaf087. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. YANG XY, Li XD, Wu BY, Yang Q, et al
    A Model to Identify Grey-Zone Patients with Chronic Hepatitis B Requiring Antiviral Therapy: A Multicentre, Retrospective Study.
    J Infect Dis. 2025 Feb 17:jiaf070. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2025
19. SUN Y, Chen Q, Liu Y, Jiao M, et al
    Decanoylcarnitine improves liver mitochondrial dysfunction in hepatitis B virus infection by enhancing fatty acid beta-oxidation.
    J Infect Dis. 2025 Jan 8:jiaf014. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. SUSPENE R, Caval V, Khalfi P, Pitre E, et al
    Cobalt chloride-mimicked hepatocyte cell hypoxia induces TREX1 leading to Hepatitis B virus restriction.
    J Infect Dis. 2025 Jan 7:jiaf002. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2024
21. ZHANG X, Nguyen VH, Kam LY, Barnett SD, et al
    Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B.
    J Infect Dis. 2024 Dec 12:jiae522. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. WANG J, Genberg BL, Feder K, Kirk GD, et al
    Impact of pandemic-induced service disruptions and behavioral changes on HCV and HIV transmission amongst people who inject drugs: a modeling study.
    J Infect Dis. 2024 Dec 6:jiae599. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. SACHITHANANDHAM J, Leep-Lazar J, Quinn J, Bowden K, et al
    Direct acting antivirals eradicate HCV from the liver quickly in people with HIV but do not fully reverse immune activation.
    J Infect Dis. 2024 Dec 4:jiae598. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
24. TERRAULT NA, Sterling R, Lok AS, Ghany MG, et al
    HBV RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal.
    J Infect Dis. 2024 Oct 30:jiae541. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. TRUSCELLO E, Wang S, Young J, Sebastiani G, et al
    Changes in hepatic steatosis before and after direct acting antiviral treatment in people living with HIV and Hepatitis C coinfection.
    J Infect Dis. 2024 Oct 17:jiae487. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. LU Y, Xin J, Liang X, Luo J, et al
    Plasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.
    J Infect Dis. 2024;230:957-969.
    PubMed     Abstract available
    
    
    
27. YAO T, Li Y, Zhang Y, Sun Y, et al
    Immunogenicity, safety, and persistence induced by triple- and standard-strength four-dose hepatitis B vaccination regimens in hemodialysis patients: A multicenter, randomized, parallel-controlled trial in Six cities in Shanxi Province.
    J Infect Dis. 2024 Oct 8:jiae494. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2024
28. HORN EK, Herrera-Restrepo O, Acosta AM, Simon A, et al
    The Burden of Hepatitis A Outbreaks in the United States: Health Outcomes, Economic Costs, and Management Strategies.
    J Infect Dis. 2024;230:e199-e218.
    PubMed     Abstract available
    
    
    
29. NAKAYA Y, Onomura D, Hoshi Y, Yamagata T, et al
    Establishment of a hepatitis B virus reporter system harboring a HiBiT-tag in the PreS2 region.
    J Infect Dis. 2024 Jul 11:jiae353. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. YAO Z, Gu Y, Lai X, Yang M, et al
    Trajectories of serum HBsAg during treatment and association with HBsAg loss in children with HBeAg-positive chronic hepatitis B: a latent class trajectory analysis.
    J Infect Dis. 2024 Jul 5:jiae349. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. 
    Correction to: Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.
    J Infect Dis. 2024 Jul 3:jiae336. doi: 10.1093.
    PubMed    
    
    
    June 2024
32. BALAGOPAL A, Thio CL
    Hepatitis B surface antigen loss: what does integration have to do with a functional HBV cure?
    J Infect Dis. 2024 Jun 24:jiae327. doi: 10.1093.
    PubMed    
    
    
    
33. OSMANI Z, Beudeker BJB, Groothuismink ZMA, de Knegt RJ, et al
    B cell activation gene signature in blood and liver of HBeAg+ immune active chronic hepatitis B patients.
    J Infect Dis. 2024 Jun 7:jiae280. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
34. GRUDDA T, Thomas DL, Kirk GD, Mehta SH, et al
    Hepatitis B virus DNA and RNA persist in liver after serologic recovery in persons with hepatitis C virus.
    J Infect Dis. 2024 May 23:jiae248. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. MBISA JL, Lapp Z, Bibby DF, Phillips LT, et al
    Identification of two novel subtypes of hepatitis C virus genotype 8 and a potential new genotype successfully treated with direct acting antivirals.
    J Infect Dis. 2024 May 8:jiae253. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2024
36. SELVAMANI SP, Khan A, Tay ESE, Garvey M, et al
    Hepatitis B virus and hepatitis C virus affect mitochondrial function through different metabolic pathways, explaining virus-specific clinical features of chronic hepatitis.
    J Infect Dis. 2024 Apr 24:jiae210. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. BEGRE L, Boyd A, Plissonnier ML, Testoni B, et al
    Circulating HBV RNA and hepatitis B core-related antigen trajectories in persons with HIV/HBV coinfection and HBsAg loss on tenofovir therapy.
    J Infect Dis. 2024 Apr 16:jiae189. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. SCHMIDT S, Mengistu M, Daffis S, Ahmadi-Erber S, et al
    Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus-Specific CD8 T-Cell Responses and High Anti-Hepatitis B Surface Antigen Titers.
    J Infect Dis. 2024;229:1077-1087.
    PubMed     Abstract available
    
    
    March 2024
39. WHITTAKER R, Midtbo JE, Klovstad H
    Monitoring progress towards the elimination of hepatitis C as a public health threat in Norway: a modelling study among people who inject drugs and immigrants.
    J Infect Dis. 2024 Mar 27:jiae147. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. KAO CM, Rostad CA, Nolan LE, Peters E, et al
    A Phase 1, Double-blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin(R)) Vaccine in Healthy US Adults.
    J Infect Dis. 2024 Mar 27:jiae148. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. KAMILI S, Wester C
    Advancing diagnosis of current HCV infection: A key to hepatitis C elimination in the United States.
    J Infect Dis. 2024 Mar 11:jiae127. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. HESTERMAN MC, Fallon BS, Lynch KM, Weller ML, et al
    Growing Awareness: Limited Testing and Screening Bias for Hepatitis Delta Virus in Utah 2000-2021.
    J Infect Dis. 2024 Mar 8:jiae023. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. ASLANIKASHVILI A, Rylander C, Manjavidze T, Gamkrelidze A, et al
    Relationship between hepatitis C infection and treatment status and COVID-19-related hospitalizations in Georgia.
    J Infect Dis. 2024 Mar 1:jiae103. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
44. HORN EK, Herrera-Restrepo O, Acosta AM, Simon A, et al
    The Burden of Hepatitis A Outbreaks in the United States: Health Outcomes, Economic Costs, and Management Strategies.
    J Infect Dis. 2024 Feb 28:jiae087. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. TU T, Ajoyan H, Nur Umami R, Veeraraghavan V, et al
    Inhibition of cellular factor TM6SF2 suppresses secretion pathways of Hepatitis B, Hepatitis C and Hepatitis D viruses.
    J Infect Dis. 2024 Feb 26:jiae098. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. COLLAZOS J, Asensi V
    Non-invasive liver fibrosis markers in the evaluation of fibrosis regression after direct-acting antiviral (DAA) therapy.
    J Infect Dis. 2024 Feb 23:jiae095. doi: 10.1093.
    PubMed    
    
    
    
47. MUSONDA T, Wallace MS, Patel H, Martin OP, et al
    New window into hepatitis B in Africa: Liver sampling combined with single cell omics enables deep and longitudinal assessment of intrahepatic immunity in Zambia.
    J Infect Dis. 2024 Feb 9:jiae054. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2024
48. RINGLANDER J, Stromberg LG, Stenback JB, Andersson ME, et al
    Enrichment reveals extensive integration of hepatitis B virus DNA in hepatitis delta-infected patients.
    J Infect Dis. 2024 Jan 25:jiae045. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2023
49. IVANOVA REIPOLD E, Shilton S, Donolato M, Fernandez Suarez M, et al
    Molecular point of care testing for hepatitis C: available technologies, pipeline and promising future directions.
    J Infect Dis. 2023 Oct 28:jiad463. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. FELD JJ
    What is needed to move toward single-step diagnosis of current HCV infection?
    J Infect Dis. 2023 Oct 13:jiad453. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. FALADE-NWULIA O, Lesko CR, Fojo AT, Keruly JC, et al
    Hepatitis C treatment in people living with HIV: Potential to eliminate disease and disparity.
    J Infect Dis. 2023 Oct 5:jiad433. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2023
52. FRICKER GP, Ghany MG, Mera J, Pinsky BA, et al
    Tools Needed to Support Same-day Diagnosis and Treatment of Current Hepatitis C Infection.
    J Infect Dis. 2023 Sep 22:jiad177. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. CARTWRIGHT EJ, Patel PR
    Opportunities for enhanced prevention and control of hepatitis C through improved screening and testing efforts.
    J Infect Dis. 2023 Sep 22:jiad199. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. JOHNSON LN, Gaynor AM, Wroblewski K, Buss SN, et al
    Maximizing Reflexive HCV RNA Testing of HCV Antibody-Reactive Samples Within United States Public Health Laboratories.
    J Infect Dis. 2023 Sep 22:jiad191. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. TERRAULT N
    Down-Classification of Hepatitis C Virus Diagnostics: Implications for Screening and Diagnosis.
    J Infect Dis. 2023 Sep 22:jiad299. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. PAGE K, Feinberg J
    What Hepatitis C (HCV) diagnostic tools are needed to advance diagnosis of current HCV infection in outreach settings and in a non-clinical setting?
    J Infect Dis. 2023 Sep 22:jiad269. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. HANDANAGIC S, Shadaker S, Drobeniuc J, Tsereteli M, et al
    Lessons learned from global hepatitis C elimination programs.
    J Infect Dis. 2023 Sep 22:jiad198. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. LOU S, Wang J, Chen J, Xie H, et al
    The Role of ALPK1 in Inhibiting Hepatitis B Virus Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting Response to Pegylated Interferon alpha Therapy.
    J Infect Dis. 2023;228:694-703.
    PubMed     Abstract available
    
    
    
59. CHIEN RN, Lu SN, Hui-Min Wu G, Yang WW, et al
    Policy and Strategy for Hepatitis C Virus Elimination at the National Level: Experience in Taiwan.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
60. KONDILI LA, Craxi L, Nava F, Babudieri S, et al
    From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
61. AARON A, Zhong H, Hiebert L, Zhuo Y, et al
    Hepatitis C Elimination in Moldova Is Feasible and Cost-Saving: A Modeling Study.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
62. QURESHI H, Mahmood H, Sabry A, Hermez J, et al
    Barriers and Strategies for Hepatitis B and C Elimination in Pakistan.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
63. WASITTHANKASEM R, Wanlapakorn N, Pimsing N, Posuwan N, et al
    Simplified Test-to-Treat Strategy for Hepatitis C in Thailand: The Phetchabun Model.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
64. NJUGUNA HN, Hiebert L, Harris A, Morgan RL, et al
    An Assessment of National Strategic Action Plans for Viral Hepatitis Elimination, 2016-2021.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
65. PRZYBYSZEWSKI EM, Chung RT
    Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
66. HUANG CF, Chen GJ, Hung CC, Yu ML, et al
    HCV Microelimination for High-risk Special Populations.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
67. ADDA D, James C, Peck R, Ali M, et al
    The Role of Nonprofit and Nongovernmental Organizations and People With Viral Hepatitis on the Path Toward Hepatitis C Virus Elimination.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
68. YU ML, Ward JW
    Sharing Lessons Learned to Build Effective Hepatitis Elimination Programs.
    J Infect Dis. 2023;228.
    PubMed    
    
    
    
69. UMUTESI J, Yu ML, Lesi O, Ward JW, et al
    Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan Africa.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
70. SPAULDING AC, Kennedy SS, Osei J, Sidibeh E, et al
    Estimates of Hepatitis C Seroprevalence and Viremia in State Prison Populations in the United States.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
71. 
    Correction to: Evidence of Residual Ongoing Viral Replication in Chronic Hepatitis B Patients Successfully Treated With Nucleos(t)ide Analogues.
    J Infect Dis. 2023 Sep 7:jiad376. doi: 10.1093.
    PubMed    
    
    
    May 2023
72. THIO CL, Taddese M, Saad Y, Zambo K, et al
    HBeAg-negative single hepatocyte analysis shows transcriptional silencing and slow decay of infected cells with treatment.
    J Infect Dis. 2023 May 2:jiad124. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.